Nachrichten zur Mirum Pharmaceuticals Aktie

Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise By Investing.com

Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise…

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

…

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

…

Mirum Pharmaceuticals misses Q4 earnings, stock falls By Investing.com

Mirum Pharmaceuticals misses Q4 earnings, stock falls…

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do…

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Heres What You Should Know

The mean of analysts price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this…

Mirum Pharmaceuticals (MIRM) is on the Move, Heres Why the Trend Could be Sustainable

Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking…

Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential

…

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

…

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

…

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest…

Mirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten

FOSTER CITY, Kalifornien, USA--(BUSINESS WIRE)--Wie Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) heute mitteilte, hat der europäische Ausschuss für Humanarzneimittel (CHMP) eine…

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

…

Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics)

Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Liver Cirrhosis - Pipeline Insight, 2024" clinical trials has been…